116 related articles for article (PubMed ID: 27070359)
1. [Diagnostic criteria for neuromyelitisoptica spectrum disorders].
Belova AN; Bojko AN; Belova EM
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2 Pt 2):32-40. PubMed ID: 27070359
[TBL] [Abstract][Full Text] [Related]
2. Neuromyelitis Spectrum Disorders.
Weinshenker BG; Wingerchuk DM
Mayo Clin Proc; 2017 Apr; 92(4):663-679. PubMed ID: 28385199
[TBL] [Abstract][Full Text] [Related]
3. The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates.
Hamid SH; Elsone L; Mutch K; Solomon T; Jacob A
Mult Scler; 2017 Feb; 23(2):228-233. PubMed ID: 27553618
[TBL] [Abstract][Full Text] [Related]
4. Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder.
You Y; Zhu L; Zhang T; Shen T; Fontes A; Yiannikas C; Parratt J; Barton J; Schulz A; Gupta V; Barnett MH; Fraser CL; Gillies M; Graham SL; Klistorner A
Ophthalmology; 2019 Jun; 126(6):801-810. PubMed ID: 30711604
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions.
Popescu BF; Guo Y; Jentoft ME; Parisi JE; Lennon VA; Pittock SJ; Weinshenker BG; Wingerchuk DM; Giannini C; Metz I; Brück W; Shuster EA; Carter J; Boyd CD; Clardy SL; Cohen BA; Lucchinetti CF
Neurology; 2015 Jan; 84(2):148-58. PubMed ID: 25503621
[TBL] [Abstract][Full Text] [Related]
6. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
[TBL] [Abstract][Full Text] [Related]
7. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
Kim SM; Waters P; Woodhall M; Kim JY; Kim JE; Yang JW; Kim JS; Sung JJ; Park KS; Lee KW
Mult Scler; 2013 Jul; 19(8):1060-7. PubMed ID: 23329699
[TBL] [Abstract][Full Text] [Related]
8. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
[TBL] [Abstract][Full Text] [Related]
9. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
10. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
Wingerchuk DM; Banwell B; Bennett JL; Cabre P; Carroll W; Chitnis T; de Seze J; Fujihara K; Greenberg B; Jacob A; Jarius S; Lana-Peixoto M; Levy M; Simon JH; Tenembaum S; Traboulsee AL; Waters P; Wellik KE; Weinshenker BG;
Neurology; 2015 Jul; 85(2):177-89. PubMed ID: 26092914
[TBL] [Abstract][Full Text] [Related]
11. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders.
Jarius S; Franciotta D; Bergamaschi R; Wildemann B; Wandinger KP
Clin Chem Lab Med; 2010 May; 48(5):659-63. PubMed ID: 20184532
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder.
Hyun JW; Jeong IH; Joung A; Kim SH; Kim HJ
Neurology; 2016 May; 86(19):1772-9. PubMed ID: 27164713
[TBL] [Abstract][Full Text] [Related]
14. Central nervous system neuroinflammatory disorders in Asian/Pacific regions.
Kim SH; Kim HJ
Curr Opin Neurol; 2016 Jun; 29(3):372-80. PubMed ID: 27128108
[TBL] [Abstract][Full Text] [Related]
15. Pruritus in neuromyelitis optica spectrum disorders and multiple sclerosis.
He M; Wu L; Huang D; Yau V; Yu S
J Clin Neurosci; 2020 Sep; 79():108-112. PubMed ID: 33070876
[TBL] [Abstract][Full Text] [Related]
16. The 2015 IPND Criteria Increases the Yield in Diagnosis of Neuromyelitis Optica Spectrum Disorder in Thai Patients Compared to the 2006 Diagnostic Criteria.
Rattanathamsakul N; Kaveeta C; Siritho S; Thakolwiboon S; Prayoonwiwat N
Mult Scler Relat Disord; 2020 Aug; 43():102218. PubMed ID: 32474289
[TBL] [Abstract][Full Text] [Related]
17. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.
Juryńczyk M; Weinshenker B; Akman-Demir G; Asgari N; Barnes D; Boggild M; Chaudhuri A; D'hooghe M; Evangelou N; Geraldes R; Illes Z; Jacob A; Kim HJ; Kleiter I; Levy M; Marignier R; McGuigan C; Murray K; Nakashima I; Pandit L; Paul F; Pittock S; Selmaj K; de Sèze J; Siva A; Tanasescu R; Vukusic S; Wingerchuk D; Wren D; Leite I; Palace J
J Neurol; 2016 Jan; 263(1):140-9. PubMed ID: 26530512
[TBL] [Abstract][Full Text] [Related]
18. AQP4 in biopsied demyelinating lesions as a diagnostic clue to NMOSD and MS: final answer?
Fujihara K; Misu T
Neurology; 2015 Jan; 84(2):110-1. PubMed ID: 25503619
[No Abstract] [Full Text] [Related]
19. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status.
Yoshimura S; Isobe N; Matsushita T; Yonekawa T; Masaki K; Sato S; Kawano Y; Kira J;
J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):29-34. PubMed ID: 23038741
[TBL] [Abstract][Full Text] [Related]
20. Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients.
Fazio R; Malosio ML; Lampasona V; De Feo D; Privitera D; Marnetto F; Centonze D; Ghezzi A; Comi G; Furlan R; Martino G
Mult Scler; 2009 Oct; 15(10):1153-63. PubMed ID: 19667009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
